Malaria, a deadly disease, is evolving to outsmart our drugs. And this is a race against time.
The latest news: Researchers are unveiling two innovative strategies to tackle the growing drug resistance in malaria. One approach introduces a groundbreaking new class of drugs, while the other focuses on a single-dose treatment using existing medications.
Novartis, a Swiss pharmaceutical giant, has developed a next-generation treatment called GanLum. In a 12-country African study, GanLum demonstrated remarkable efficacy against the malaria parasite, potentially blocking its spread. However, it's still over a year away from being licensed and available to the public.
But here's the catch: The parasite is becoming resistant to current drugs, leaving experts worried. Dr. David Sullivan, a malaria specialist, warns that the situation is akin to walking on thinning ice.
GanLum is administered as a packet of powder-like granules, taken once daily for three days. However, ensuring patient compliance is challenging, as many stop taking the medication after feeling better. This non-adherence can fuel drug resistance and worsen curable cases.
In West Africa, a team of researchers tested a different approach: a one-time treatment using a combination of four widely available malaria drugs. This single-dose strategy proved effective in curing the disease.
Malaria, transmitted by mosquitoes, can cause fever, chills, and flu-like symptoms. If untreated, it can be fatal, especially in children in sub-Saharan Africa. The battle against malaria has been ongoing, with new drugs emerging, but the parasite keeps evolving resistance.
For instance, chloroquine resistance was once widespread, leading to over 1.8 million deaths annually. Then, artemisinins arrived, significantly reducing global malaria deaths. However, even these drugs are now facing partial resistance, and malaria death rates are rising in some regions.
Dr. Ghyslain Mombo-Ngoma's study in Gabon tested a single-dose treatment combining artemisinin with three other antimalarials. The results showed a slightly higher cure rate compared to the standard three-day treatment.
Controversially, while this single-dose approach seems promising, some experts argue that it may only be a temporary solution due to existing resistance to some of its components.
Novartis' GanLum combines a new drug, ganaplacide, with lumefantrine, a long-acting medication. In a large African study, it achieved a cure rate of over 97%, outperforming a common artemisinin-based treatment. It also showed effectiveness against drug-resistant mutant parasites.
Side effects were similar to those of current antimalarials, with a higher incidence of vomiting attributed to the drug's taste. Novartis is working on flavoring solutions to address this.
These new treatments can enhance existing malaria prevention methods, such as bed nets and vaccines. However, funding cuts from the US and other sources may hinder progress, impacting drug resistance monitoring and treatment accessibility.
The question remains: Can we stay ahead of malaria's evolving resistance? Share your thoughts on these promising yet challenging developments.
